Last updated: February 27, 2026
What is the drug associated with NDC 70677-1242?
NDC 70677-1242 corresponds to Zulresso (brexanolone) infusion, indicated for the treatment of postpartum depression in adult women. It is marketed by Sage Therapeutics.
Market Size and Demand Drivers
Addressable Patient Population
- Postpartum depression (PPD): Affects approximately 10-15% of women postpartum.
- United States estimates: About 4 million births annually, resulting in 400,000 to 600,000 affected women.
- Treatment gap: Only roughly 20-30% of eligible women receive approved therapies, indicating significant unmet demand.
Market Penetration Factors
- Coverage and Reimbursement: As of 2023, Medicare and private insurers have begun standardizing reimbursement, reducing out-of-pocket costs.
- Clinical Adoption: Early adoption by psychiatric and obstetric specialists based on recent guidelines integrating Zulresso as a first-line treatment for severe PPD.
Competitive Landscape
- Existing treatments: Psychotropic medications (SSRIs), therapy, and electroconvulsive therapy.
- Zulresso's differentiation: First FDA-approved drug specifically for PPD, administered via hospital or outpatient infusion.
Market Size Estimation
| Parameter |
Value |
Source |
| Annual births in the U.S. |
4 million |
CDC (2022) |
| PPD prevalence rate |
12% |
American Psychiatric Assoc. |
| Eligible for Zulresso |
480,000 women annually |
Calculated |
| Current utilization rate |
10% (early phase adoption) |
Industry estimates |
Projected eligible patients: 48,000 annually with potential to increase as awareness grows.
Pricing Trends and Projections
Current Pricing
- List price per infusion: Approximately $34,000 to $35,000 (per the manufacturer's release).
- Treatment course: Single infusion administered over 60 hours.
- Reimbursement: Insurance companies often cover based on negotiated prices; patient co-pays vary.
Price Drivers
- Regulatory status: FDA approval in 2019 facilitated premium pricing.
- Market competition: No direct competitors currently approved; potential entrants could pressure price.
- Manufacturing costs: High due to drug complexity and infusion requirement.
Future Price Trends (2023-2027)
| Year |
Expected Price per Infusion |
Key Assumptions |
Source |
| 2023 |
$34,500 |
Current pricing maintained |
Sage Therapeutics |
| 2024 |
$33,000 |
Slight discounts as competition emerges |
Industry analysts |
| 2025 |
$31,500 |
Pricing pressure from generic/biosimilar entrants |
Patent expiry considerations |
| 2026 |
$30,000 |
Market saturation |
Market research |
| 2027 |
$28,000 |
Increased competition and biosimilar options |
Patent cliff prediction |
Price Sensitivity Factors
- Insurance reimbursement policies influence net prices.
- Hospital and infusion center contracts may lead to discounts.
- Patient out-of-pocket costs influence access and demand growth.
Regulatory and Policy Impact
- Market access: CMS inclusion in Medicare Part B supports broader coverage, reducing price sensitivity.
- Reimbursement rates: Changes in coding or reimbursement rates by CMS could impact net revenue.
- Potential biosimilar approval: Biosimilars are unlikely within the next 3-5 years due to complex manufacturing but could affect prices long-term.
Conclusion
The Zulresso market remains relatively high-priced due to its novelty, indication specificity, and lack of direct competitors. Prices are projected to decline gradually as market dynamics shift, especially with potential biosimilar development and increased competition.
Key Takeaways
- The U.S. market for Zulresso supports an annual revenue potential of approximately $1-$2 billion at current prices, contingent on adoption rate growth.
- Price projections indicate a decline of roughly 20-25% over five years, influenced by competitive pressures and policy changes.
- Market expansion depends heavily on increasing awareness, insurer reimbursement policies, and strategic physician outreach.
FAQs
Q1: What are the primary factors influencing Zulresso’s price?
A1: Manufacturing complexity, market exclusivity, FDA approval status, and insurer reimbursement policies.
Q2: How many patients can Zulresso realistically reach annually?
A2: Up to 48,000 women in the U.S., with potential for growth as awareness and adoption increase.
Q3: How likely is biosimilar competition to impact prices?
A3: Low in the next 3-5 years due to manufacturing complexity; higher prospects beyond that timeline.
Q4: What role do insurance companies play in price stabilization?
A4: They negotiate reimbursement rates and influence patient out-of-pocket costs, impacting overall market dynamics.
Q5: Could policy changes affect Zulresso’s market significantly?
A5: Yes. CMS policy shifts or new guidelines could expand coverage, increasing demand and stabilizing prices.
Sources
- CDC. (2022). Birth Data for the United States. Retrieved from https://www.cdc.gov/nchs/pressroom/nchs_data.htm
- American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.
- Sage Therapeutics. (2022). Zulresso Pricing and Reimbursement Data.
- Industry Reports on Postpartum Depression Market. (2022). MarketWatch.
